Namilumab

Generic Name
Namilumab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1206681-39-1
Unique Ingredient Identifier
MED485W763
Background

Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

First Posted Date
2022-04-28
Last Posted Date
2024-02-02
Lead Sponsor
Kinevant Sciences GmbH
Target Recruit Count
1
Registration Number
NCT05351554
Locations
🇺🇸

Kinevant Study Site, Charleston, South Carolina, United States

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

Phase 2
Active, not recruiting
Conditions
Sarcoidosis, Pulmonary
Interventions
Drug: Namilumab
Drug: Placebo
First Posted Date
2022-04-06
Last Posted Date
2024-11-01
Lead Sponsor
Kinevant Sciences GmbH
Target Recruit Count
107
Registration Number
NCT05314517
Locations
🇬🇧

Kinevant Study Site, London, United Kingdom

Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate

First Posted Date
2015-03-19
Last Posted Date
2019-02-05
Lead Sponsor
Takeda
Target Recruit Count
7
Registration Number
NCT02393378

Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

First Posted Date
2015-03-04
Last Posted Date
2018-09-14
Lead Sponsor
Takeda
Target Recruit Count
108
Registration Number
NCT02379091

Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis

Phase 2
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: Namilumab
Drug: Placebo
First Posted Date
2014-05-02
Last Posted Date
2017-04-07
Lead Sponsor
Takeda
Target Recruit Count
122
Registration Number
NCT02129777
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy